[1] |
Younossi ZM. Non-alcoholic fatty liver disease-a global public health perspective[J]. J Hepatol, 2019, 70: 531-544.
|
[2] |
李想,李晔.非酒精性脂肪性肝病中自噬与铁死亡相互作用的研究进展[J]. 基础医学与临床,2023, 43: 1294-1298.
|
[3] |
Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis[J]. N Engl J Med, 2017, 377: 2063-2072.
|
[4] |
Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease[J]. Hepatology (Baltimore, Md), 2018, 67: 123-133.
|
[5] |
Bertot LC, Adams LA. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease[J]. Expert Rev Gastroenterol Hepatol, 2019, 13: 179-187.
|
[6] |
Raza S, Rajak S, Upadhyay A, et al. Current treat-ment paradigms and emerging therapies for NAFLD/NASH[J]. Front Biosci(Landmark Edition), 2021, 26: 206-237.
|
[7] |
Wargny M, Ducluzeau PH, Petit JM, et al. Circulating PCSK9 levels are not associated with the severity of hepatic steatosis and NASH in a high-risk population[J]. Atherosclerosis, 2018, 278: 82-90.
|
[8] |
Tsuchida T, Lee YA, Fujiwara N, et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J]. J Hepatol, 2018, 69: 385-395.
|
[9] |
Grewal T, Buechler C. Emerging insights on the diverse roles of proprotein convertase subtilisin/kexin type 9 (PCSK9) in chronic liver diseases: cholesterol metabolism and beyond[J]. Int J Mol Sci, 2022, 23:1070.doi:10.3390/ijms23031070.
|
[10] |
秦可欣,陈小翠,崔元峰,等.PPARα基因敲除诱导小鼠肝脏脂质蓄积的作用研究[J].新疆医科大学学报, 2023,46:1267-1272.
|
[11] |
Wang Q, Ou Y, Hu G, et al. Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice[J]. Br J Pharmacol, 2020, 177: 1806-1821.
|
[12] |
Rex J, Lutz A, Faletti L E, et al. IL-1β and TNFα differentially influence NF-κB activity and fasl-induced apoptosis in primary murine hepatocytes during LPS-induced inflammation[J]. Front Physiol, 2019, 10: 117.doi:10.3389/fphys.2019.00117.
|
[13] |
Cai J, Zhang XJ, Li H. Role of innate immune signaling in non-alcoholic fatty liver disease[J]. Trends Endocrinol Metab: TEM, 2018, 29: 712-722.
|